ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

NCI-Approved Clinical Trials

April 26, 2002

Breast Implants Don’t Cause Tissue Disorders, NCI Finds

October 29, 2004

Interim Analysis of Phase III Data Preferable For Accelerated Approval, FDA’s Pazdur Says

September 6, 2002

HHS Awards $85 Million For Research to Eliminate Health Disparities

November 15, 2002

In Brief: Over Half Of Ovarian Cancer Patients Staged Incorrectly; Senate Gets Funding Resolution

April 12, 1985

In Brief: Coalition Begins Campaign To Educate Public

February 3, 1995